How big is SCYNEXIS, Inc.?

As of Jun 18, SCYNEXIS, Inc. has a market capitalization of 29.27 million and reported net sales of 2.64 million with a net profit of -27.09 million over the last four quarters.

Market Cap: As of Jun 18, SCYNEXIS, Inc. has a market capitalization of 29.27 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, SCYNEXIS, Inc. reported net sales of 2.64 million and a net profit of -27.09 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 55.08 million and total assets of 90.64 million.

What does SCYNEXIS, Inc. do?

SCYNEXIS, Inc. is a micro-cap pharmaceutical company focused on the discovery and development of anti-infectives. As of March 2025, it reported net sales of $0 million and a net loss of $5 million, with a market cap of $29.27 million.

Overview:<BR>SCYNEXIS, Inc. is engaged in the discovery, development, and commercialization of anti-infectives within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -5 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 29.27 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.80 <BR>Return on Equity: -67.78% <BR>Price to Book: 0.58<BR><BR>Contact Details:<BR>Address: 1 Evertrust Plz Fl 13, JERSEY CITY NJ: 07302-3051 <BR>Tel: 1 201 8845485 <BR>Fax: 1 919 5448697 <BR>Website: http://www.scynexis.com/

Should I buy, sell or hold SCYNEXIS, Inc.?

Who are in the management team of SCYNEXIS, Inc.?

As of March 2022, the management team of SCYNEXIS, Inc. includes Dr. Pamela Kirby (Chairman), Dr. Marco Taglietti (CEO), and directors Armando Anido, Laurent Arthaud, Steven Gilman, Ann Hanham, and David Hastings. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of SCYNEXIS, Inc. includes the following individuals:<BR><BR>- Dr. Pamela Kirby, Chairman of the Board<BR>- Dr. Marco Taglietti, President, Chief Executive Officer, and Director<BR>- Mr. Armando Anido, Director<BR>- Mr. Laurent Arthaud, Director<BR>- Dr. Steven Gilman, Director<BR>- Ann Hanham, Director<BR>- Mr. David Hastings, Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is SCYNEXIS, Inc. overvalued or undervalued?

As of August 8, 2024, SCYNEXIS, Inc. is considered risky due to its overvaluation and negative financial metrics, including a low EV to EBITDA ratio of 0.13, underperformance compared to peers and the S&P 500, and a year-to-date return of -9.92%.

As of 8 August 2024, the valuation grade for SCYNEXIS, Inc. has moved from attractive to risky, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued, particularly given its negative financial metrics. Key ratios include a Price to Book Value of 0.71, an EV to EBIT of 0.13, and an EV to EBITDA of 0.13, all of which suggest that the company is struggling to generate positive returns relative to its valuation.<BR><BR>In comparison to peers, SCYNEXIS, Inc. has a notably low EV to EBITDA ratio of 0.13, while CytomX Therapeutics, Inc., which is rated very attractive, boasts a much higher EV to EBITDA of 4.6280. Other peers such as Chimerix, Inc. and Aquestive Therapeutics, Inc. also show negative valuations, but SCYNEXIS's performance stands out as particularly weak. Additionally, the company's stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -9.92% versus the S&P 500's 12.22%, reinforcing the notion of its overvaluation.

Is SCYNEXIS, Inc. technically bullish or bearish?

As of September 11, 2025, SCYNEXIS, Inc. shows a neutral technical trend with mixed indicators, underperforming the S&P 500, suggesting a cautious investment approach.

As of 11 September 2025, the technical trend for SCYNEXIS, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed indicators. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The RSI shows no signal on the weekly chart but is bullish on the monthly. However, the daily moving averages are mildly bearish, and the KST indicates a bearish monthly trend. Additionally, the Bollinger Bands present a mildly bullish signal on the weekly but a mildly bearish signal on the monthly.<BR><BR>In terms of performance, SCYNEXIS has underperformed the S&P 500 across multiple periods, with a 1-week return of -7.63% compared to the S&P 500's 1.05%, and a 1-year return of -30.57% versus the S&P 500's 17.14%. Overall, the mixed signals suggest a cautious approach is warranted.